Monitor for continued post-exercise selling or any new open-market transactions; absence of buying and presence of coordinated C-suite selling may signal lack of conviction, though likely part of pre-arranged plan.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 23 $15.56entry
- T+1 · 9mo ago +1.35%α +0.61% · $15.77
- T+5 · 9mo ago +3.21%α +2.59% · $16.06
- T+20 · 8mo ago +6.68%α +10.63% · $16.60
- T+60 · 6mo ago +71.98%α +63.73% · $26.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite executives at KalVista Pharmaceuticals, the CFO and Chief Commercial Officer, sold shares worth $89,385 in the past week, following recent option exercises. The sales are part of a planned disposition after exercising options, not open-market selling, and no new insider buying was detected.
Key Financial Metrics
Key Facts
- CFO Brian Piekos sold 1,767 shares for $27,507 at $15.57/share on 2026-02-23
- CCO Nicole Sweeny sold 3,975 shares for $61,878 at $15.57/share on 2026-02-23
- Both executives exercised stock options on 2026-02-21 and 2026-02-22 (totaling 11,250 shares) at $0 price, indicating prior grant exercise
- Total insider sell activity in cluster: $89,385
- No insider buying activity observed in the past 7 days
Financial Impact
$89,385 in insider sales from option exercise proceeds
Risk Factors
- Perception of insider减持 despite being post-exercise, potentially affecting sentiment
- Minor dilution from recently exercised options
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (5 trades, 7d window) | cluster-KALV-1771980197249 |
Track record
12 reports on KALV
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +4.15% at T+5 after the Apr 17, 2026 report. 3 of 6 went positive at some point.
Filters
- Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
- Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
- Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
- May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
- May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
- Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
- Apr 17, 202630w ago Insider Cluster Bearish 6/10 Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers